secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001846253-24-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023
--------------------------------------------------------------------------------

- Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.
- H1 2024 revenue $11.4M vs $23.9M (prior year included $10M TECVAYLI milestone); net loss $32.6M ($0.32/sh).
- Cash $57.2M at June 30; expects 2024 opex slightly below 2023, cash use similar to 2023 ex-$35M milestone.
- New platform licenses with DAAN Bio, Topaz Therapeutics, HanAll Biopharma; post-Q2 deals with 92Bio and Memorial Sloan Kettering.
- GSK discontinued Nav1.1 program (OmniAb retains co-ownership); Roche returning Kv7.2 rights (not due to scientific reasons).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000071/0001846253-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000071/oabi-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001846253-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer